ClinicalTrials.gg
RecruitingNCT06214988SELSAUpdated May 21, 2025

Selective Defunctioning Stoma in Low Anterior Resection for Rectal Cancer

An interventional study of selective approach defunctioning stoma in Rectal Cancer, sponsored by Skane University Hospital. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Skane University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Rectal Neoplasms with a site in Sweden — 15 open to participants now, 22 under way, 4 of them phase 3. Rectal Neoplasms · Sweden.

Planned enrollment
21st of 40
212 · median 233
Started
2024
with 1 other
No phase
20 of 64
10 open now
Primary completion
2027-12
later than 14 of 21 live
Registered
58th of 64
by date

Among the 64 studies in Rectal Neoplasms with a site in Sweden, this one is the 21st largest by planned enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2024, is one of 20 with no phase, reaches primary completion later than 14 of the 21 other live ones, and was the 58th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

15 of the 64 studies in Rectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Rectal Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this observational trial with a nested randomized controlled trial is to investigate a selective approach of defunctioning stoma in low anterior resection in rectal cancer patients. The primary outcome is a hybrid so-called textbook outcome; stoma-free survival at two years without major LARS, reflecting a functionally appropriate outcome after low anterior resection for rectal cancer. Secondary outcomes include anastomotic leakage, postoperative mortality, reinterventions, stoma-related complications, quality of life measures, LARS, and permanent stoma rate up to two years after index surgery.

Read the detailed description

Systematic use of defunctioning stoma after low anterior resection for rectal cancer has been shown to reduce symptomatic anastomotic leakage and associated interventions. However, accumulating data suggest that this comes at the price of worse bowel dysfunction, a higher rate of permanent stomas and kidney injury. We aim to study whether a selective strategy of defunctioning stoma use might lead to fewer adverse consequences, while still being safe for patients.

This is a multicentre international prospective trial including a non-blinded randomised clinical trial. All patients with a primary rectal cancer planned for low anterior resection with colorectal or coloanal anastomosis are eligible. Patients enter a prospective observational study, in which a randomised clinical trial is nested. Patients eligible for randomisation are aged below 80 years, have an American Society of Anesthesiologists' fitness grade I or II, have no unresected distant disease, and have a predicted lower risk of anastomotic leakage. Patients will be randomised 1:1 to either an experimental arm with no defunctioning stoma or to a control arm with a defunctioning stoma. The randomisation is computer-generated with a concealed sequence and stratified by participating hospital and radiotherapy use. The main outcome is the composite measure of 2-year stoma-free survival without major low anterior resection syndrome (LARS). Secondary outcomes include anastomotic leakage, postoperative mortality, reinterventions, stoma-related complications, quality of life measures, LARS, and permanent stoma rate up to two years after index surgery. To be able to state superiority of any study arm regarding the main outcome, with 90% statistical power and assuming 25% attrition, we aim to enrol 212 patients.

This study has been approved by Ethical Review Authority in Sweden (2023-04347-01) and seeks permission in Norway and Danmark, respectively. The results will be disseminated through patient associations, popular science, the broader medical community, and conventional scientific channels.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • anterior resection
  • defunctioning stoma
  • selective approach
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with rectal cancer planned for a low anterior resection with anastomosis by TME with any surgical approach

Additional inclusion criteria for randomised part of the study:

  • Patients aged less than 80 years
  • Patients with American Society of Anesthetists' (ASA) fitness grade I or II as determined by the anaesthesiologist or the surgeon
  • Patients without clear radiological signs of distant disease before rectal cancer surgery (previous surgery is no exclusion criterion)
  • Anastomotic leak risk score of 0-1
  • Willingness to be randomised

Exclusion criteria

Exclusion Criteria:

  • Insufficient command of Swedish, Norwegian, Danish or English to understand questionnaires or consent
  • Emergency rectal resection (tumour resection due to large bowel obstruction, perforation, etc)
  • Pregnancy or breastfeeding Additional exclusion criteria for randomised part of the study
  • Previous pelvic irradiation (due to e.g. gynaecological or urological cancer)
  • Preoperative tumour perforation or pelvic sepsis
  • Beyond TME surgery and/or concurrent resection of other organ
  • Concurrent treatment (prednisone-equivalent dosage ≥10 mg daily)
  • Planned postoperative chemotherapy
  • Smoking not completely ceased four weeks before surgery
  • Excessive alcohol consumption with social and medical consequences (as judged by the surgeon in charge) Intraoperative exclusion criteria for randomised part of the study

    ->2 staple firings for rectal transection

  • Intraoperative blood loss ≥250 ml for minimally invasive surgery
  • Intraoperative blood loss ≥500 ml for open or converted surgery
  • More than one intraabdominal anastomosis performed
  • Incomplete doughnuts
  • Air-leak test positive
  • Any significant intraoperative adverse event at the discretion of the operating surgeon (e.g. ureterotomy, bowel or tumour perforation, major medical event - pulmonary embolism, cardiac arrhythmia) (Gawria, 2022)
  • TME with anastomosis ultimately not done
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    selective approach to defunctioning stoma

    With randomisation to this experimental arm (selective approach), no defunctioning stoma is constructed.

    Procedure: selective approach defunctioning stoma

  • No intervention
    routine use of defunctioning stoma

    With randomisation to this control arm (systematic approach), a defunctioning stoma is constructed using the marked stoma site. A loop ileostomy is fashioned using an ileal loop close to the ileocecal valve, while a loop colostomy can be derived from either the transverse or a redundant left colon.

Interventions

  • Procedureselective approach defunctioning stoma

    With randomisation to this experimental arm (selective approach), no defunctioning stoma is constructed.

06

What researchers measure

Primary outcomes

  1. textbook outcome; stoma-free survival at two years without major LARS

    extant stoma, alive, and a LARS score at 30 or lesn has stabilised as well for those without a stoma in situ. no extant stoma, alive, and a LARS score at 30 or less at the time point two years after the anterior resection.

    Time frame: 2 year

Secondary outcomes

  1. Anastomotic leakage

    ISREC grading

    Time frame: 1,3,12 and 24 months

  2. Complications

    Clavien-Dinco

    Time frame: 1,3,12 and 24 months

  3. Length of hospital stay

    total days in hospital

    Time frame: until discharge within 90 days

  4. Postoperative mortality

    death

    Time frame: 3 months

  5. Major Low Anterior Resection Syndrome

    domain score scale 0-42 points, \>30 points indicate a bad functional outcome i.e. major LARS

    Time frame: 12 and 24 months

  6. Quality of life by European Organization for Research and Treatment of Cancer- ColoRectal 29 (EORTC-CR29)

    EORTC-CR29 domain scores in scales 0-100 points, a high score for the global health status /quality of life represents a high quality of life, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: 12 and 24 months

  7. Quality of Recovery-15 Swedish (QoR15swe)

    Difference from baseline in total score 0-150 points, higher value indicating faster recovery

    Time frame: 1 month

  8. Adjuvant chemotherapy for high-risk patients

    Clinical assessment categorisation

    Time frame: 12 months

  9. Renal function

    Creatinine (mg/L)

    Time frame: 12 and 24 months

  10. Stay out of hospital

    total days of alive and out of hospital

    Time frame: 24 months

  11. Stoma in situ

    proportion

    Time frame: 24 months

  12. Recurrence (local and distant)

    Clinical assessment categorisation

    Time frame: 36 and 60 months

  13. Overall survival

    Clinical assessment categorisation

    Time frame: 36 and 60 months

  14. Quality of life by European Organization for Research and Treatment of Cancer- Cancer30 (EORTC-C30)

    EORTC-C30 domain scores in scales 0-100 points, a high score for the global health status /quality of life represents a high quality of life, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: 12 and 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Unidentified raw data may be shared upon request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: When study complete including primary and secondary endpoints.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 39 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2023
First posted
Jan 22, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2030
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06214988
Lead sponsor
Skane University Hospital
Collaborators
Umeå University, Lund University, Göteborg University, Ersta Hospital, Sweden, Copenhagen University Hospital at Herlev, Linkoeping University, Oslo University Hospital, Örebro University, Sweden
Responsible party
Pamela Buchwald (associate professor, senior consultant surgeon, Skane University Hospital) — Principal investigator
First posted
Jan 22, 2024
Start date
Sep 1, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
May 21, 2025

Study contacts

Caroline Nilsson, RN
Contact
caroline.n.nilsson@skane.se
004640331000
Pamela Buchwald, MD PhD
principal investigator · Skåne University Hospital, Lund University
Martin Rutegård, MD PhD
principal investigator · Umeå University Hospital, Umeå University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion